Telaprevir
Improves Hepatitis C Treatment Response
June
28, 2011
|
HCV
Drug TMC649128 Enters Phase 1b Trial
June
28, 2011
|
Coffee
Improves Response to Hepatitis C Treatment
June
21, 2011
|
Causes
of Death Among People with Hepatitis B and C
June
17, 2011
|
Vertex
Licenses Alios HCV Protease Inhibitors
June
17, 2011
|
Sitges
Meeting Discusses European Access to New Hepatitis C Drugs
June
17, 2011
|
HCV
Protease Inhibitor Danoprevir Promising in Early Trial
June
14, 2011
|
PSI-7977
Trial Adds New Regimens
June
14, 2011
|
Updated
PegIntron Label Psychiatric Warning
June
14, 2011
|
BI201335
Shows Potent Activity against HCV
June
3, 2011
|
Prolonged
Entecavir for Slow Responders
June
3, 2011
|
PSI-7977
+ BMS-790052 Trial for Hepatitis C
June
3, 2011
|
Boceprevir
(Victrelis) Patient Assistance Program
May
31, 2011
|
Telaprevir
(Incivek) Patient Assistance Program
May
31, 2011
|
Caffeine
and Liver Disease in People with Hepatitis C
May
31, 2011
|
Telaprevir
(Incivek) Approved for Hepatitis C
May
24, 2011
|
FDA
OKs New Abbott HCV Test
May
24, 2011
|
European
Committee Recommends Boceprevir (Victrelis)
May
20, 2011
|
TMC435
Boosts Hepatitis C Post-Treatment Response
May
20, 2011
|
Quality
of Life for Children on Hepatitis C Treatment
May
20, 2011
|
Boceprevir
(Victrelis) Approved for Hepatitis C
May
17, 2011
|
DHHS
Releases Viral Hepatitis Action Plan
May
17, 2011
|
Screen
for HCV Based on Age, Not Risk Factors
May
13, 2011
|
Is
Hepatitis C Rising among Young People?
May
13, 2011
|
Longer
Interferon Treatment Raises Hepatitis C Cure Rate
May
10, 2011 |
EASL
Releases New Hepatitis C Clinical Practice Guidelines
May
6, 2011
|
FDA
Committee Unanimously Recommends Telaprevir (Incivek)
May
3, 2011
|
Boceprevir
for HCV Wins Unanimous FDA Committee Recommendation
April
29, 2011
|
BI
201335 for Hepatitis C Moves into Phase 3 Trials
April
29, 2011
|
Viral
Load, HIV Status, but not IL28B Predict Perinatal HCV
Transmission
April
29, 2011
|
Boosted
ABT-450 Improves Early Response to Interferon for Hepatitis
C
April
26, 2011
|
Idera
Delays Study of TLR9 Agonist IMO-2125 for Hepatitis C
April
26, 2011
|
FDA
Hearings Next Week on Boceprevir and Telaprevir for HCV
April
22, 2011
|
Tegobuvir
Works Well in Triple and Quad Regimens for HCV
April
22, 2011
|
Boosted
Danoprevir Improves Response in Prior Null Responders
April
19, 2011
|
Once-Daily
BI 201335 Ups Response to Interferon for Hepatitis C
April
15, 2011
|
BMS-790052/BMS-650032
Combo Cures Hepatitis C without Interferon
April
8, 2011
|
BMS-790052
+ Pegylated Interferon/Ribavirin Works Well for First
HCV Treatment
April
8, 2011
|
First
Sustained Response Data for Polymerase Inhibitor Mericitabine
April
5, 2011
|
Polymerase
Inhibitor PSI-7977 Works Well with Interferon or Companion
Drug
April
5, 2011
|
Telaprevir
Improves HCV Cure Rates Regardless of IL28B Status
April
5, 2011
|
Pegylated
Interferon Lambda Boosts Response with Fewer Side Effects
April
5, 2011
|
Telbivudine
Label Adds Resistance Warning
April
5, 2011
|
Telaprevir
Combo Works for HCV Patients with Prior Treatment Failure
April
1, 2011 |
Boceprevir
Improves Response to Interferon-Based HCV Therapy
April
1, 2011 |
Boceprevir
Helps Hepatitis C Patients with Cirrhosis
April
1, 2011 |
4-Drug
Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
April
1, 2011
|
Statin
Boosts Response to Pegylated Interferon/Ribavirin
April
1, 2011 |
Gene
Regulation Mechanism Promotes Liver Cancer
March
29, 2011 |
TAG
Pipeline Report Outlines Future of Hepatitis C Treatment
March
25, 2011 |
Early
Menopause Linked to Poor Hepatitis C Treatment Response
March
25, 2011 |
FDA
Committee Sets Review Dates for HCV Drugs Boceprevir and
Telaprevir
March
18, 2011 |
New
Phase 2b Study of Experimental Hepatitis C Vaccine ChronVac-C
March
18, 2011 |
HCV
Protease Inhibitor Boceprevir Improves Response for Treatment-Naive
and Non-responders
March
15, 2011 |
U.S.
Hepatitis C Incidence Declined 10-fold Over 2 Decades
March
11, 2011 |
HCV
Polymerase Inhibitor INX-189 Gets FDA Fast-Track Status,
TMC649128 Enters Phase 1a Trial
CROI
2010
March
4, 2011 |
Tibotec
Starts Phase 3 Clinical Trials of HCV Protease Inhibitor
TMC435
February
25, 2011
|
FDA
Approves HCV Rapid Antibody Test for Fingerstick Blood
Samples
February
25, 2011
|
Treatment
of Recurrent Hepatitis C after Liver Transplantation
February
18, 2011
|
Little
Change in Hepatitis C Risk among Injection Drug Users
February
11, 2011
|
San
Francisco Hepatitis C Task Force Issues Recommendations
February
11, 2011
|
Hepatitis
C Patients May Have Increased Risk of Stroke
February
1, 2011
|
Anadys
Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598
February
1, 2011
|
Peretinoin
Improves Hepatocellular Carcinoma in People with Mild
Liver Impairment
January
28, 2011
|
HCV
Protease Inhibitor Telaprevir Will Get Priority Review
in U.S. and Canada
January
25, 2011
|
Body
Weight May Not Affect Hepatitis C Treatment if Ribavirin
Dose Is Adequate
January
25, 2011
|
HCV
Polymerase Inhibitor INX-189 Looks Promising in Early
Study
January
21, 2011
|
Nucleic
Acid Testing Identifies Hepatitis B Virus Sooner in Blood
Donors
January
21, 2011
|
HCV
Protease Inhibitor Boceprevir Accepted for Priority Review
in U.S. and Europe
January
14, 2011
|
Company
Collaboration to Test BMS-790052 + PSI-7977 Combo for
Hepatitis C
January
14, 2011
|
Peregrine
Starts Phase 2 Trial of Monoclonal Antibody Hepatitis
C Treatment
January
14, 2011
|
Anemia
during Hepatitis C Treatment Predicts Sustained Response
to Pegylated Interferon/ribavirin
January
11, 2011
|
Pharmasset
Starts Trial of HCV Polymerase Inhibitor PSI-7977 without
Interferon
January
11, 2011
|
Vertex
Ends Clinical Trial Arm Testing Dual Telaprevir Plus VX-222
Regimen
January
7, 2011
|
Experts
Devise Roadmap for Development of Direct-acting Hepatitis
C Drugs
January
7, 2011 |
Pre-treatment
with Ribavirin Improves Response to Interferon-based Therapy
for Hepatitis C
December
14, 2010
|
Artificial
Liver Device Improves Survival for Hepatitis B and C Patients
with Decompensated Disease
December
14, 2010
|
Hepatitis
C Experts Sought for FDA Advisory Committee
December
10, 2010
|
Pegylated
Interferon Lambda for Hepatitis C Produces Good Response
with Minimal Blood Toxicity
December
10, 2010
|
Menopause
and Obesity Predict HCV Relapse after Interferon-based
Therapy
December
10, 2010
|
Drinking
More Coffee Linked to Improved Response to Hepatitis C
Treatment
December
3, 2010 |
Vertex
Completes FDA Submission of Telaprevir New Drug Application
November
19, 2010
|
Interim
Results Show TMC435 Works Well in Treatment-experienced
Hepatitis C Patients
November
19, 2010
|
Do
IL28B Gene Variations Affect Liver Disease Progression
in People with Hepatitis C?
November
19, 2010
|
IL28B
Gene Patterns and Liver Transplant Outcomes in Hepatitis
C Patients
November
19, 2010
|
AASLD
2010 - Talking Slides Update
November
16, 2010
|
Directing-acting
Drug Combos Suppress HCV without Interferon, but Resistance
Remains a Concern
November
16, 2010 |
Higher
Doses May Overcome Poor Response to Interferon in Hepatitis
C Patients with Unfavorable IL28B Gene Pattern
November
12, 2010 |
Preliminary
Results Show Promising Response to Therapeutic Hepatitis
C Vaccine GI-5005
November
12, 2010 |
Early
Analysis Finds Good Outcomes with Once-daily Dosing of
HCV Protease Inhibitor TMC435
November
5, 2010 |
Sustained
Response to Hepatitis C Therapy Is Key to Improved Survival
after Liver Transplantation
November
5, 2010 |
Boceprevir
Improves Response to Interferon-based Therapy and Allows
Many Patients to Reduce Duration of Treatment
November
5, 2010 |
Telaprevir
Increases Sustained Response Rates and Shortens Treatment
Duration for Newly Treated Hepatitis C Patients
November
5, 2010 |
Vertex
Begins Trial of Telaprevir for Treatment-naive Chronic
Hepatitis C Patients
October
29, 2010 |
FDA
Approves Roche's Second-generation Hepatitis C Viral Load
Test
October
29, 2010 |
AASLD
Liver Meeting Offers On-Site Registration This Week
October
29, 2010 |
Can
Chronic Hepatitis C Patients with Genotypes 2 or 3 Benefit
from Shorter Interferon Treatment?
October
26, 2010 |
Direct-acting
Drugs Danoprevir plus RG7128 Suppress HCV without Interferon
October
26, 2010 |
Weight-based
Taribavirin Works as Well as Ribavirin for Chronic Hepatitis
C, but Causes Less Anemia
October
15, 2010 |
Hepatitis
C Virus Causes Brain Inflammation Leading to Neuron Injury
October
15, 2010 |
Roche
Acquires Rights to InterMune HCV Protease Inhibitor Danoprevir
October
8, 2010 |
AASLD
and Trust for America's Health Call for Action on Hepatitis
B and C
October
8, 2010 |
Weight-based
Taribavirin Works as Well as Ribavirin for Chronic Hepatitis
C, but Causes Less Anemia
October
1, 2010 |
Three-quarters
of People with Hepatitis C in the U.S. Have Hard-to-treat
Genotype 1
October
1, 2010 |
October
1 Is AASLD Liver Meeting Discount Registration Deadline
September
28, 2010 |
Vancouver
Hepatitis C Treatment Program for Injection Drug Users
Proves Popular and Successful
September
28, 2010 |
October
1 Is AASLD Liver Meeting Discount Registration Deadline
September
28, 2010 |
Vancouver
Hepatitis C Treatment Program for Injection Drug Users
Proves Popular and Successful
September
28, 2010 |
First
MicroRNA Hepatitis C Therapy Enters Phase 2 Clinical Development
September
24, 2010 |
Heterosexual
Sex Not a Major Risk Factor for Hepatitis C Virus Transmission
September
21, 2010 |
FDA
Issues Guidance for Development of Direct-acting Antiviral
Drugs for Hepatitis C
September
17, 2010 |
Natural
history of Hepatitis C Acquired through Injection Drug
Use
September
14, 2010 |
Telaprevir
Combination Therapy Boosts Sustained Response Rates for
Previously Treated Hepatitis C Patients
September
10, 2010 |
FDA
Suspends Trials of Experimental HCV Regimen IDX184 plus
IDX320 Due to Liver Toxicity Concerns
September
10, 2010 |
Week
4 Rapid Virological Response Predicts Sustained Response
to Interferon-based Hepatitis C Treatment
September
4, 2010 |
People
Who Naturally Clear Hepatitis C Virus Have Lower Risk
of Death than Chronic Patients
August
31, 2010 |
Pegylated
Interferon plus Ribavirin Has High Sustained Response
Rates in Children with Hepatitis C
August
31, 2010 |
IL28B
Gene Pattern May Influence Susceptibility to Hepatitis
C Virus Genotypes
August
31, 2010 |
Only
Fittest Hepatitis C Virus Strains Re-infect New Liver
after Transplantation
August
27, 2010 |
Protease
Inhibitor TMC435 Shows Potent and Sustained Efficacy for
Genotype 1 Chronic Hepatitis C
August
24, 2010 |
Silymarin
Milk Thistle Extract May Inhibit Hepatitis C Virus Entry
into Cells
August
20, 2010 |
International
Study Links Tattoos with Higher Risk of Hepatitis C
August
17, 2010 |
HCV
Polymerase Inhibitor PSI-7977 Receives FDA Fast Track
Designation
August
17, 2010 |
Addition
of HCV Protease Inhibitor Telaprevir Can Shorten Interferon-based
Hepatitis C Treatment
August
17, 2010 |
HCV
Protease Inhibitor Boceprevir Increased Sustained Response
to
Interferon-based Therapy in Phase 3 Studies
August
6, 2010 |
Hepatitis
C Virus Prevalence Has Decreased among U.S. Blood Donors
Since the Early 1990s
August
6, 2010 |
Combination
Therapy with HCV Polymerase Inhibitor ANA598 Produces
12-week Sustained Response in Small Study
August
6, 2010 |
Chronic
Hepatitis C Virus Infection Is Associated with Early Atherosclerosis
July
30, 2010 |
Pharmasset
Starts New Phase 1b Clinical Trial of HCV Polymerase Inhibitor
PSI-938
July
30, 2010 |
Hope
Against Hepatitis C
July
30, 2010 |
Hepatitis
C Virus Can Remain Viable for Months in a Liquid Environment
at Low Temperatures
July
20, 2010 |
Asian
Patients Respond as Well as Whites to Interferon-based
Therapy for Chronic Hepatitis C
July
20, 2010 |
Response
at Week 8 Accurately Predicts Sustained Response to Pegylated
Interferon plus Ribavirin for Hepatitis C
July
20, 2010 |
Eiger
HCV NS4B Inhibitor Exhibits Synergy with Experimental
HCV Protease Inhibitors
July
9, 2010 |
Consensus
Interferon (Infergen) Label Changed to Include Data on
Dosing with Ribavirin
July
9, 2010 |
Immune
Cells Show Signs of Senescence after Liver Transplantation
July
9, 2010 |
Chronic
Hepatitis C Linked to Increased Risk of Kidney Cancer
July
6, 2010 |
Sustained
Response to Antiviral Therapy Prevents Esophageal Varices
in Hepatitis C Patients with Cirrhosis
July
6, 2010 |
FDA
Approves First Rapid Hepatitis C Virus Antibody Blood
Test
July
2, 2010 |
Treating
Hepatitis C in People with Compensated Cirrhosis Is Most
Cost-effective Approach
July
2, 2010 |
House
of Representatives Holds Hearing on the "Secret Epidemic"
of Viral Hepatitis
July
2, 2010 |
Blood-boosting
Adjuvant Therapies Can Improve Response to Interferon-based
Treatment for Hepatitis C
July
2, 2010 |